In vitro extreme drug resistance assay to taxanes or platinum compounds for the prediction of clinical outcomes in epithelial ovarian cancer: a prospective cohort study

2009 ◽  
Vol 135 (11) ◽  
pp. 1513-1520 ◽  
Author(s):  
Hee Seung Kim ◽  
Tae Joong Kim ◽  
Hyun Hoon Chung ◽  
Jae Weon Kim ◽  
Byung Gie Kim ◽  
...  
2019 ◽  
Vol 181 ◽  
pp. 112-119 ◽  
Author(s):  
Henriette Strøm Kahr ◽  
Ole Bjarne Christiansen ◽  
Anni Grove ◽  
Victor Iyer ◽  
Christian Torp-Pedersen ◽  
...  

2009 ◽  
Vol 18 (11) ◽  
pp. 1777-1782 ◽  
Author(s):  
Kim N. Danforth ◽  
Catherine Schairer ◽  
Arthur Schatzkin ◽  
James V. Lacey

2014 ◽  
Vol 7 (1) ◽  
Author(s):  
Jing Xie ◽  
Elizabeth M Poole ◽  
Kathryn L Terry ◽  
Teresa T Fung ◽  
Bernard A Rosner ◽  
...  

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Zhi-Yong Zeng ◽  
Shao-Dan Feng ◽  
Gong-Ping Chen ◽  
Jiang-Nan Wu

Abstract Background Early identification of patients who are at high risk of poor clinical outcomes is of great importance in saving the lives of patients with novel coronavirus disease 2019 (COVID-19) in the context of limited medical resources. Objective To evaluate the value of the neutrophil to lymphocyte ratio (NLR), calculated at hospital admission and in isolation, for the prediction of the subsequent presence of disease progression and serious clinical outcomes (e.g., shock, death). Methods We designed a prospective cohort study of 352 hospitalized patients with COVID-19 between January 9 and February 26, 2020, in Yichang City, Hubei Province. Patients with an NLR equal to or higher than the cutoff value derived from the receiver operating characteristic curve method were classified as the exposed group. The primary outcome was disease deterioration, defined as an increase of the clinical disease severity classification during hospitalization (e.g., moderate to severe/critical; severe to critical). The secondary outcomes were shock and death during the treatment. Results During the follow-up period, 51 (14.5%) patients’ conditions deteriorated, 15 patients (4.3%) had complicated septic shock, and 15 patients (4.3%) died. The NLR was higher in patients with deterioration than in those without deterioration (median: 5.33 vs. 2.14, P < 0.001), and higher in patients with serious clinical outcomes than in those without serious clinical outcomes (shock vs. no shock: 6.19 vs. 2.25, P < 0.001; death vs. survival: 7.19 vs. 2.25, P < 0.001). The NLR measured at hospital admission had high value in predicting subsequent disease deterioration, shock and death (all the areas under the curve > 0.80). The sensitivity of an NLR ≥ 2.6937 for predicting subsequent disease deterioration, shock and death was 82.0% (95% confidence interval, 69.0 to 91.0), 93.3% (68.0 to 100), and 92.9% (66.0 to 100), and the corresponding negative predictive values were 95.7% (93.0 to 99.2), 99.5% (98.6 to 100) and 99.5% (98.6 to 100), respectively. Conclusions The NLR measured at admission and in isolation can be used to effectively predict the subsequent presence of disease deterioration and serious clinical outcomes in patients with COVID-19.


Sign in / Sign up

Export Citation Format

Share Document